№ lp_2_3_19124
File format: docx Character count: 4019 File size: 92 KB
Year: 2026
Region / city: Missouri
Document Type: Proposal
Organization: MO HealthNet
Author: MO HealthNet, Conduent
Target Audience: MO HealthNet participants, healthcare providers
Period of validity: Ongoing
Approval Date: January 20, 2026
Revision Date: May 21, 2008
Criteria Status: Revision of Existing Criteria
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Pathway for prescribing acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine in the treatment of Alzheimer’s disease, Parkinson’s Disease dementia and Dementia with Lewy bodies
Year: 2018
Region / city: London
Theme: Dementia care, pharmacology
Document type: Clinical guideline
Organization / institution: London Dementia Clinical Network (NHS England and Improvement London Region)
Author: Delia Bishara (Consultant Pharmacist, South London and Maudsley NHS Foundation Trust)
Target audience: Healthcare professionals involved in dementia care
Effective period: 2018–present
Approval date: Not specified
Date of amendments: Not specified
SmartPA Criteria Proposal Drug/Drug Class: NSAIDs PDL Edit
Year: 2026
Region / City: MO HealthNet
Theme: NSAIDs, Pharmacology, Health Policy
Document Type: Proposal
Institution: MO HealthNet, Conduent
Author: MO HealthNet and Conduent
Target Audience: Healthcare Providers, Policy Makers, MO HealthNet Participants
Period of Validity: Indefinite
Approval Date: January 20, 2026
Modification Date: None
SmartPA Criteria Proposal Drug/Drug Class: Fibromyalgia Agents PDL Edit
Year: 2026
Region / City: Missouri
Theme: Fibromyalgia Treatment
Document Type: Medical Criteria Proposal
Author: MO HealthNet and Conduent
Target Audience: MO HealthNet participants, healthcare providers
Approval Date: January 20, 2026
Period of Validity: Not specified
Change Date: Not specified
Topics: N-Methyl-D-Aspartate acetylcholinesterase DrugDrug